Sensorion, Novasep ink gene therapy agreement

By The Science Advisory Board staff writers

October 27, 2020 -- Sensorion and Novasep have signed an agreement for the manufacturing of adeno-associated virus (AAV) vectors covering a gene therapy program that targets OTOF, the gene encoding the otoferlin protein. Mutations of OTOF can lead to severe congenital hearing loss.

OTOF-GT, Sensorion's most advanced program, aims to restore the expression of otoferlin in the inner hair cells of the ear, where it plays an essential role in hearing.

Under the terms of the agreement, Novasep will be in charge of developing and manufacturing the two AAV vectors designed for Sensorion's OTOF-GT product and will supply drug product batches to support preclinical and clinical studies. Development and manufacturing activities include cell culture, AAV expression, purification, aseptic distribution, and quality control.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here